Stochastic processes wherein the size of the state space is changing as a function of time offer models for the emergence of scale-invariant features observed in complex systems. I consider such a sample-space reducing (SSR) stochastic process that results in a random sequence of strictly decreasing integers {x(t)},0≤t≤τ, with boundary conditions x(0)=N and x(τ) = 1. This model is shown to be exactly solvable: P_{N}(τ), the probability that the process survives for time τ is analytically evaluated. In the limit of large N, the asymptotic form of this probability distribution is Gaussian, with mean and variance both varying logarithmically with system size: 〈τ〉∼lnN and σ_{τ}^{2}∼lnN. Correspondence can be made between survival-time statistics in the SSR process and record statistics of independent and identically distributed random variables.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1103/PhysRevE.93.042131 | DOI Listing |
BMC Public Health
January 2025
Department of Statistics, Borana University, Borena, Oromia Region, Ethiopia.
Introduction: Hypertension is among the most significant non-communicable public health issues worldwide. High blood pressure, or hypertension, has been associated with severe health consequences, including death, aneurysms, stroke, chronic renal disease, eye damage, heart attack, heart failure, peripheral artery disease, and vascular dementia. Consequently, this study aimed to investigate the predictors linked to survival time and the progression of blood pressure measurements in hypertensive patients.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
Background: Lewy body pathology (LBP) is common in autosomal dominant (ADAD) or sporadic Alzheimer disease (sAD). LBP seems to be the most frequent co-pathology in sAD and even in the relatively young ADAD population, where other co-pathologies are rare. Knowledge of neuropathological distribution patterns of LBP and associated survival and genetic characteristics in both AD variants is incomplete.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Florida, College of Public Health and Health Professions and College of Medicine, Gainesville, FL, USA.
Background: The restricted mean disease progression (RMDP) is a measure of disease progression from baseline to a pre-specified follow-up visit. The RMST is a new statistical tool for survival analysis that is increasingly used in clinical trials. The RMST can be easily interpreted as the average survival time of patients from baseline to the pre-specified follow-up time.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Background: Subjective cognitive decline (SCD) is recognized to be in the Alzheimer's disease (AD) cognitive continuum. An international working group known as the SCD-initiative recently proposed "SCD plus" features, including report of memory problems, recent SCD relative to conversion, SCD over age 60, and consistent SCD over time, that increase the risk for future objective cognitive decline. These have not been fully assessed in a large community-based setting.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Developmental and Educational Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain.
Background: The importance of coincidence of cognitive complaints between participants without objective impairment and their informants in predicting progression remains unclear (Nosheny et al, 2022). Our objective was to determine whether agreement in dyadic reporting at baseline can predict survival time to progression to MCI or dementia.
Method: A sample of 145 participants from the CompAS Study was included in a survival analysis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!